Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label, Single Arm Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage I To III Resectable Merkel Cell Carcinoma

NCT06151236 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT06151236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06151236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label, Single Arm Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage I To III Resectable Merkel Cell Carcinoma
Lead sponsor
Melanoma Institute Australia
Phase
Phase 2
Overall status
Recruiting
Start date
March 11, 2024
Completion date
April 30, 2034
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

merkel cell carcinoma